Anti-chromatin antibodies in systemic lupus erythematosus: A useful marker for lupus nephropathy

Annals of the Rheumatic Diseases

Volumn 62, Issue 5, 2003, Pages 431-434

  Cervera, R ^a   Vinas O ^a   Ramos Casals, M ^a   Font, J ^a   Garcia Carrasco M ^a   Siso A ^a   Ramirez F ^a   Machuca, Y ^a   Vives, J ^a   Ingelmo, M ^a   Burlingame, R W ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHROMATIN ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BLOOD; CHILD; CHROMATIN; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; CHILD; CHROMATIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME;

EID: 0037404913     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.5.431     Document Type: Article

References (30)

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine (Baltimore) 1993;72:113-24.
2. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
3. Van Venrooij WJ, Sillekens PTG. Small nuclear RNA associated proteins: autoantigens in connective tissue diseases. Clin Exp Rheumatol 1989;7:635-45.
4. Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002;11:145-51.
5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus. A multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999;78:167-75.
6. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966;45:1732-40.
7. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
10. Amoura Z, Piette J-C, Bach J-F, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999;42:833-43.
11. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000;43:76-84.
12. Bruns A, Bläss S, Hausdorf G, Burmester GR, Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-15.
13. Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB, Asmann KJ, et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994;94:568-77.
14. Mohan C, Adams S, Stanik V, Datta SK. Nucleosame: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
15. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993;91:1687-96.
16. Morel L, Blenman KR Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, SLE1, is a cluster of functionally related genes. Proc Natl Acad Sci USA 2001;98:1787-92.
17. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification af Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
18. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
19. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
20. American Rheumatism Association glossary committee. Signs and symptoms. Dictionary of the Rheumatic Disease 1982;1:1-80.
21. Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: light and immunofluorescence microscopic observations. Am J Kid Dis 1982;2(suppl 1):135-41.
22. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. Clin Exp Rheumatol 1992;10:527-39.
23. Cervera R, Font J, López-Soto A, Casals F, Pallarés L, Bové A, et al. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus. Prospective analysis of a series of 100 patients. Ann Rheum Dis 1990;49:109-13.
24. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC subcommittee for the standardization of lupus anticoagulants. Thromb Haemost 1991;65:320-2.
25. Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, et al. A muiticenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-17.
26. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
27. Hmida Y, Schmit P, Gilson G, Humbel RL. Failure to detect antinucleosome antibodies in scleroderma: comment on the article by Amoura et al. Arthritis Rheum 2002;46:280-2.
28. Wallace DJ, Lin HC, Shen GQ, Peter JB. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994;37:1795-7.
29. Schlumberger W, Daehnrich C, Suer W, Frahm S Stoecker W. Autoantibodies against nucleosomes are pathognomonic for SLE - a 2nd generation ELISA shows no reactivity with sera from scleroderma patients. In: Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, eds. Proteomics to molecular epidemiology: relevance of autoantibodies. Dresden: Pabst Science Publishers, 2002:639-40.
30. Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon. Comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000;43:420-8.